Actively Recruiting
Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer
Led by Xijing Hospital · Updated on 2025-06-10
71
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single-center, open-label, prospective, clinical cohort study. It enrolled patients in three subgroups: triple negative, HR+HER2-, or HR-HER2+ subtypes, who will receive neoadjuvant treatment according to guidelines. Patients in each subgroup will be divided into two categories: those responsive to neoadjuvant therapy and those resistant to it, based on the efficacy of the treatment. Tumor tissue samples from all enrolled patients before and after neoadjuvant therapy will be collected. We will explore transcriptomic differences in neoadjuvant therapy responders or resisters under the same treatment regimen, as well as transcriptomic changes in tumor tissue before and after treatment, based on single-cell sequencing and spatial transcriptomic technology.
CONDITIONS
Official Title
Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary enrollment and ability to understand and sign informed consent
- Female, aged 25 to 70
- Meet indications for neoadjuvant therapy as defined by 2023 CSCO Breast Cancer Guidelines
- No previous systemic treatment for breast cancer
- Neoadjuvant treatment regimen matches study requirements for breast cancer subtypes
- Tumor specimens can be obtained by biopsy or surgery
- A complete pathological report is available
You will not qualify if you...
- Did not sign the informed consent form
- Tumor specimens cannot be obtained by biopsy or surgery
- Severe systemic infections or other serious diseases
- Previous cytotoxic chemotherapy, endocrine therapy, biological therapy, or radiotherapy
- Does not meet indications for neoadjuvant therapy
- Neoadjuvant treatment regimen not included in this study
- Other conditions deemed unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xijing hospital
Xi'an, Shaanxi, China, 710032
Actively Recruiting
Research Team
J
Ju liang J L Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here